The Clinical TMS Society conducted a survey on typical clinical TMS practices at its Annual Meeting in Toronto Canada on May 28th 2015. The Clinical Standards and Insurance committees created the survey with contributions from Drs Tarique Perera, Max Okasha, Michelle Cochran, and Kevin Kinback. A total of 68 members representing over 75 TMS practices participated in the survey using PollEverywhere software. Only full members who were practicing clinicians owning and operating out patient clinical were eligible to vote. The results were tabulated by the society administrators and presented in the following table.

	Clinical TMS Society S	urvey	
Questions	Answers	Number	Percent
1. How long	Less than one year	10	14.71
have you	1-2 years	10	14.71
been doing	2-3 years	11	16.18
TMS?	3-4 years	17	25
	More than 4 years	20	29.41
	Total Responses	68	
	Unique Participants	68	
2. Which	NouroStar	62	65.06
devices do	NeuroStar	11	65.96 11.7
you use?	Brainsway	5	5.32
(check all	Magventure	7	7.45
that apply)	MagPro Magstim	7	7.45
	Other	2	2.13
		2	2.13
	Total Responses	94	
	Unique Participants	70	
3. In your	Manufacturer training	17	26.15
opinion, what should	Product training plus CME course	48	73.85
be the	Total Responses	67	
required training for the prescribing			
physician?	Unique Participants	67	
4. What	Manufacturer training	17	10.83
should be	Manufacturer training plus 1-5 observed		
the	treatments	30	19.11
required	Manufacturer training plus 5+ observed treatments	25	15.92
training	Current CPR or BLS	30	19.11
for TMS	HIPPA Training	37	23.57
Operators?	University or Industry sponsored course	18	11.46
(Check all			
that apply	Total Responses	157	
,	Unique Participants	67	
			0.70
5. What	No college degree	14	9.79
are the degrees that your TMS	Bachelors	43	30.07
	Masters	23	16.08
	Medical Technician/LVN	20	13.99
	RN	24	16.78

operator(s	MD	12	8.39
) have?			
(Check all	Total Responses	147	
that			
apply)	Unique Participants	70	
6.	Operator treats only when TMS Provider is in		
Autonomy	the building	6	8.96
of the TMS	Operator can treat when Provider is absent		10.10
operator:	but other MD is in the building	9	13.43
operacori	Operator can treat alone, but with immediate	42	62.60
	access to prescriber Operator can treat without immediate access	42	62.69
	to prescriber	10	14.93
		10	11.55
	Total Responses	66	
	Unique Participants	66	
7. Who	Physician only	53	80.3
can	Physician or Technician	13	19.7
perform			
the initial	Total Responses	67	
		-	
Motor			
Threshold			
determinat			
ion and			
TMS coil			
placement			
?	Unique Participants	67	
8. What is	Operator provides updates or progress notes		
your level	every day	37	27.82
of	Operator provides updates or progress notes		
physician	every week Physician checks in with patient every day, or	14	10.53
oversight?	2-3 times/week	25	18.8
over orgine.	Physician checks in with patient once every 1-	25	10.0
	2 weeks	32	24.06
	Clinical meetings with treatment team are held	_	
	on regular basis	25	18.8
	Total Responses	133	
	Unique Participants	69	
9. Do you	Yes	42	62.69
have	No	25	37.31
written			
	Total Responses	67	

	1		
Standard			
Operating			
Procedure			
s for your			
TMS			
	Unious Deutisia ata	67	
practice?	Unique Participants	67	
10. What	None	8	5.41
additional	Crash cart	5	3.38
equipment	Defibrillator	8	5.41
	Medications to treat seizure, etc	10	6.76
do you	Oxygen	14	9.46
have in	Suction	9	6.08
the TMS	Full crash cart with intubation equipment	2	1.35
room?	EMG	9	6.08
(Check all	EEG	4	2.7
that	Music Player (MP3 or otherwise)	37	2.7
apply)	Television or other video	42	28.38
appiy)		42	20.30
	Total Responses	143	
	Unique Participants	68	
11. A	Adequate dose and duration of at least 4		
sufficient	weeks	18	27.27
trial	Adequate dose and duration of at least 6-8		
means:	weeks	31	46.97
means.	Medication intolerance even if inadequate	. –	
	dose/duration	17	25.76
	Tabal Daamanaa	<u> </u>	
	Total Responses	68	
	Unique Participants	68	
12.	Lack of RESPONSE after 6-8 weeks of		
	medications at adequate dose	34	50.75
Antidepres	Lack of REMISSION after 6-8 weeks of		00170
sant	medications at adequate dose	16	23.88
failure	Medication intolerance or side effects even if		
means:	inadequate dose/duration	17	25.37
	Total Responses	67	
	Unique Participants	67	
10 14/1			7.46
13. What is the minimum number of	No minimum, TMS is first line	5	7.46
	1 antidepressant, TMS is second line	16	23.88
	2-3 antidepressants	31	46.27
	4 or more antidepressants	8	11.94
treatment	4 or more antidepressants plus augmentation	_	10 45
	agents	7	10.45

f=:1	Must fail MAO or ECT	0	0
failures (adequate		0	0
	Total Responses	67	
trials)		0,	
before you			
recommen			
d TMS?	Unique Participants	67	
14. How	5.5cm anterior to motor cortex on MT		
-	determination	39	58.21
do you	6cm or more anterior to motor cortex on MT		
locate the	determination	13	19.4
DLPFC?	Use 10-20 EEG guided methods (Beam		
	method)	13	19.4
	Use stereotactic coil navigation systems	2	2.99
	Total Responses	62	
	Unique Participants	62	
	Unique Farticipants	02	
15. If	Yes	28	45.16
there is a	No	34	54.84
bilateral			
treatment,	Total Responses	104	
do you			
check MT			
separately			
on each			
side?	Unique Participants	67	
Side :		07	
16. When	Never rechecked during treatment	5	4.81
do you	Routinely rechecked midway through acute	-	
recheck an	course	26	25
MT?	Rechecked if there is lack of response	38	36.54
	Rechecked if medications are changed	35	33.65
	T + 1 D	107	
	Total Responses	127	
	Unique Participants	69	
17. What	Neuronetics standard: Left DLPFC at 10Hz,		
is your	120% of MT, 3000 pulses	45	35.43
typical treatment parameter	Higher frequency on left (>10Hz)	9	7.09
	Standard 10Hz but >3000 pulses	18	14.17
	Right DLPFC 1Hz 110% of MT	12	9.45
?	Bilateral Standard Left and Right	15	11.81
:	Alternating Left or Right based on prominent		0.00
	anxiety or other reason	11	8.66
	Brainsway standard: Left DLPFC at 18Hz	8	6.3
	Other	9	7.09

	Total Responses	62	
	Unique Participants	62	
		02	
18.	Never shorten the interval	28	45.16
Decreasin	20-25 sec (Neuronetics)	11	17.74
g inter-	15-19 sec (Neuronetics or Brainsway)	12	19.35
train	10-14 sec (Neuronetics or Brainsway)	9	14.52
interval:	Less than 10 sec (Neuronetics or Brainsway)	2	3.23
incervar.			
	Total Responses	127	
	Unique Participants	67	
19. What	4 weeks, since Randomized Control Trials	_	
is your	(RCTs) show plateau of benefits after 4 weeks	5	7.58
target	6 weeks, since RCTs show additional benefit up to 6 weeks	28	42.42
length of	7-8 weeks since Observational Studies and	20	42.42
TMS	cross over data show benefit beyond 6 weeks	5	7.58
course?	With measurement-based care, the treatment		
	duration is keyed to symptomatic remission	28	42.42
	Total Responses	68	
	Unique Participants	68	
20.	Usually wash out antidepressant medications	2	2.04
Antidepres	prior to TMS	2	2.94 13.24
sant	Taper medications during the course of TMS Increase medications during TMS course	9	2.94
medication	Medications unchanged during the course of	2	2.94
managem	TMS	55	80.88
ent during			
acute TMS	Total Responses	174	
course	Unique Participants	78	
	· · · · ·	·	
21. What	None	2	1.15
rating	Beck Depression Inventory	39	22.41
scales do	Hamilton Depression Rating Scale	24	13.79
you	MADRS	11	6.32
typically	PHQ-9	52	29.89
use for	Sheehan	6	3.45
depression	Zung	11	6.32
? (Check	CGIS	7	4.02
all that	Other	22	12.64
apply.)			
appiy.)	Total Responses	174	
	Unique Participants	68	

22 When	2 weeks or loss	1 5	21.13
22. When do you make	2 weeks or less	15	
	3 weeks	30	42.25
	4 weeks	22	30.99
treatment	5-6 weeks	0	0
changes in	more than 6 weeks	1	1.41
non-	Protocol is never altered for non-response	3	4.23
responder			
s?	Total Responses	71	
5!	Unique Participants	71	
23. Typical	Stop TMS	3	1.2
changes in	Recheck MT level	46	18.4
TMS non-	Adjust coil location - anterior, lateral, or both	23	9.2
responder	Increase pulses to >3000	44	17.6
	Increase dose to >120% MT	11	4.4
s: (Check	Increase to >5 sessions per week	5	2
all that	Switch to right sided, low frequency (1 Hz)	13	5.2
apply)	Switch to bilateral: left high-frequency and		
	right low-frequency	36	14.4
	Switch to alternating sessions of left high-		
	frequency and right high- frequency	5	2
	Add or increase medications	36	14.4
	Add adjunctive therapy: phototherapy, CBT,		
	biofeedback, exercise, nutritional		
	supplements, etc.	28	11.2
	Total Responses	274	
	Unique Participants	65	
		·	
24. In	2 weeks or less	21	30.88
your	3 weeks	30	44.12
experience	4 weeks	15	22.06
	5 weeks	1	1.47
, what is	6 weeks or more	1	1.47
the typical		-	1117
length of	Total Responses	66	
treatment		00	
before			
response			
is first			
seen?	Unione Deuticia entr		
Seens	Unique Participants	66	
			0.00
25. In	3 weeks or less	6	9.09
your experience , what is the typical	4-5 weeks	36	54.55
	6 weeks	23	34.85
	more than 6 weeks	1	1.52
	Total Responses	69	

length of			
TMS			
treatment			
before			
remission			
is first			
	Unious Deuticine ate	60	
seen?	Unique Participants	69	
26.	Abrupt	7	10.14
Terminatio	Taper over 2-3 weeks	53	76.81
n of TMS	Taper over 4+ weeks	9	13.04
in			
	Total Responses	63	
responder			
s or		6.0	
remitters:	Unique Participants	63	
27. In TMS	Immediately	21	33.33
_	After extending treatment 1-2 weeks	33	52.38
non-	After extending treatment more than 2 weeks	9	14.29
responder	After extending treatment more than 2 weeks		14.25
s, who	Total Responses	63	
have			
completed			
6 weeks of			
treatment,			
TMS is			
terminated			
?	Unique Participants	63	
20 1-	Ctop TMC	1	6.25
28. In	Stop TMS Extend course but maintain same protocol	4 27	6.35 42.86
partial	Extend course after altering protocol (i.e.	27	42.00
responder	changing dose and/or location)	22	34.92
s who	Stop acute course and start maintenance TMS	10	15.87
have	•		
completed	Total Responses	68	
the acute			
phase of 6			
weeks, do			
you:	Unique Participants	68	
29.	Never: the acute course length is fixed	4	3.39
Reasons	Non-response	39	33.05
for	Responders who have not remitted	50	42.37
extending	In order to taper off medications	15	12.71
the acute	Other	10	8.47

course of	Total Responses	118	
TMS			
beyond 6			
weeks			
(check all			
that			
apply)	Unique Participants	68	
30. What	Maintenance TMS	25	37.88
is your	Maintenance medications	40	60.61
primary	No TMS treatments, medications tapered	1	1.52
• •			
strategy to avoid	Total Responses	66	
relapse?	Unique Participants	66	
•			
31. TMS is	Early relapse (i.e. mild symptoms		
reintroduc	deterioration)	60	90.91
ed in:	Full relapse (i.e. criteria for major depression are met)	6	9.09
		0	9.09
	Total Responses	69	
	Unique Participants	69	
32. Do	Return to the original settings	27	39.13
you redo	Redo the motor location and MT	42	60.87
the MT for	Tabel Damage		
a booster	Total Responses	66	
session?	Unique Participants	66	
22	1.2 tractments	4	6.06
33.	1-2 treatments 3-5 treatments	4 22	6.06 33.33
Number of boosters	Weekly treatments until response	5	7.58
	Clusters of treatments until response	19	28.79
given:	Weekly treatments until remission	2	3.03
	Clusters of treatments until remission	14	21.21
	Total Responses	64	
	Unique Participants	64	
34. When	Never	6	9.38
do you	All remitters	16	25
consider	Responders that do not remit	2	3.13
maintenan	Patients with a history of frequent relapse (4	25	
ce TMS (in	or more in one year) Patients who are not on maintenance	35	54.69
the	medications	5	7.81
absence of			

relapsing	Total Responses	68	
symptoms			
)?	Unique Participants	68	
35. Typical	Weekly	12	17.65
frequency	Every 2-3 weeks	9	13.24
of	Monthly	18	26.47
maintenan	Bimonthly	2	2.94
ce	Tapers over several months from weekly to		
sessions:	monthly	4	5.88
3033101131	Titrated to patient's response	23	33.82
	Total Responses	63	
	Unique Participants	63	
36.	One session at a time	42	66.67
Number of	Cluster of 2 sessions	12	19.05
sessions	Cluster of 3 or more sessions	9	14.29
at each	Total Responses	68	
maintenan			
се			
interval:	Unique Participants	68	